Drug Trial Radar · NCT05252364
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Dec 14, 2021
Primary completion
Jan 22, 2024
Study completion Jan 22, 2024
Sponsor
- Lead sponsor
- Hinova Pharmaceuticals Aus Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this Phase 1 study is to evaluate the safety, PK, and anti-tumor activity of 12 weeks of daily oral dosing with HP518 after selecting the RP2D of HP518 based on assessments of multiple dose escalation in patients with progressive mCRPC.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
HP518 - Dose EscalationDrug
Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort assignment.
HP518 - Dose expansionDrug
Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidences of Protocol-defined DLT during the DLT assessment period , characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drugTime frame: 28 days
- Incidence of Treatment-Emergent Adverse Events characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousnessTime frame: Through study completion, an average of 1 year
- Incidence of laboratory abnormalities, characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Through study completion, an average of 1 year
- Incidence of vital signs abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Time Frame: Through study completion, an average of 1 year
- Incidence of ECG (PR, QRS, QT, and QTcF intervals) abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Through study completion, an average of 1 year
- Proportion of patients showing a PSA decline of ≥50% between baseline and Week 12 of dosing with HP518.Time frame: 12 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Border Medical Oncology
Albury, New South Wales, Australia
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Macquarie University
Macquarie Park, New South Wales, Australia
Peter McCallum Cancer Center
Melbourne, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.